Global Glioblastoma Multiforme Share 2025, Forecast To 2034
26 Mar, 2025
What Fueled The Previous Growth In The Glioblastoma Multiforme Market?
The glioblastoma multiforme market has seen considerable growth due to a variety of factors.
• In recent times, the market size for glioblastoma multiforme has witnessed notable expansion. It is anticipated to rise from $2.50 billion in 2024 to $2.71 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.3%.
The previous growth can be tied to numerous factors such as a rising number of glioblastoma multiforme cases, improvements in healthcare facilities, heightened awareness, better reach to progressive treatments, and an aging population base.
How Does the Forecast Look for the Glioblastoma Multiforme Market?
The glioblastoma multiforme market is expected to maintain its strong growth trajectory in upcoming years.
• The market for glioblastoma multiforme is anticipated to demonstrate robust growth over the coming years, with a projected value of $3.69 billion in 2029, signifying an 8.1% compound annual growth rate (CAGR). This growth during the prediction period can be credited to the escalating numbers of brain and other nervous system cancers, growing acceptance of surgical procedures, increasing awareness, early disease detection, and a surge in R&D activities. The forecast period is expected to showcase significant trends such as the emergence of advanced medical technology, progress in imaging techniques, tailored medicine, use of AI in diagnosis, and breakthroughs in technology and science.
What Are The Leading Drivers Of Growth In The Glioblastoma Multiforme Market?
The prevalence of brain disorders is predicted to fuel the growth of the glioblastoma multiforme market. Brain disorders, which impact the brain's structure or function causing cognitive, emotional, or physical disabilities, are on the rise due to factors like growing aging population, extended lifespan, lifestyle aspects, and enhanced diagnostic capabilities. Comprehending brain disorders promotes glioblastoma multiforme (GBM) research, paving way for superior early diagnosis techniques, novel treatments, and improved patient outcomes. Reseach on neurological conditions can help identify genetic and molecular triggers leading to GBM. For example, Dementia Australia, a non-profit organization based in Australia, revealed in February 2025 that roughly 433,300 Australians suffer from dementia, a number that could potentially reach 812,500 by 2054. Furthermore, the occurrence of early onset dementia is reported to be around 29,000 in 2025, likely to rise to 41,000 by 2054. Hence, the increasing cases of brain disorders are set to propel the glioblastoma multiforme market growth.
How Are The Segments Defined Within The Global Glioblastoma Multiforme Market?
The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
What Trends Are Reshaping The Future Of The Glioblastoma Multiforme Market?
Leading corporations in the glioblastoma multiforme market are prioritizing the creation of advanced treatments such as CAR T-cell therapies, with the aim to fulfill the important medical requirements associated with aggressive cancer. CAR T-cell therapies are a type of immunotherapy where a patient's T-cells are altered to more efficiently identify and destroy cancerous cells. In June 2023, for example, Chimeric Therapeutics Limited, a biotech firm based in Australia, embarked on a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy to tackle recurrent or progressing glioblastoma multiforme (GBM). The multi-center trial aims to test the safety and effectiveness of the therapy and establish the suggested Phase 2 dosage. The initial Phase 1a findings indicated disease stability, which the trial aims to build upon for further development. The collected data will be utilized by the company to plan a registration trial and to obtain regulatory feedback.
Who Are the Key Players In The Glioblastoma Multiforme Market?
Major companies operating in the glioblastoma multiforme market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Bristol Myers Squibb Company
• AstraZeneca PLC
• Novartis International AG
• Eli Lilly and Company
• Amgen Inc.
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Zydus Pharmaceuticals (USA) Inc.
• Accord Healthcare Inc.
• Sumitomo Dainippon Pharma Oncology Inc.
• Karyopharm Therapeutics Inc.
• ITM Isotope Technologies Munich SE
• Azurity Pharmaceuticals Inc.
• Genenta Science S.p.A.
• Chimeric Therapeutics Limited
• VBI Vaccines Inc.
What Is The Most Dominant Region In The Glioblastoma Multiforme Market?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.